Boca Raton, Fla.-based Cancer Treatment Centers of America and Foundation Medicine are collaborating on an educational campaign to raise awareness regarding the potential of precision medicine.
Foundation Medicine recently received FDA approval for its FoundationOne CDx genomic test, which is a broad companion diagnostic test that helps clinicians make targeted and immunotherapy decisions for each unique cancer patient. The test can also be used to determine therapeutic clinical trial opportunities for patients. CTCA, a nationwide cancer care network with five hospitals, is an early adopter of FoundationOne CDx.
The awareness campaign includes specific patient case studies focused on how CTCA has used Foundation Medicine genomic profiling to help inform treatment plans. These case study videos will be distributed through the New York Times website, which helped produce the videos, and in several digital and social media initiatives.
"Precision medicine, and the move to a more personalized, targeted approach to cancer care, is becoming more ubiquitous over time," said Vincent Miller, MD, CMO of Foundation Medicine. "It's essential that every stakeholder in a patient's care plan — physician, patient and care team — is knowledgeable about the benefits of genomic profiling, and that they can take this approach at the time of diagnosis of advanced disease."